What is the share price of Bafna Pharmaceuticals Ltd (BAFNAPH) today?
The share price of BAFNAPH as on 3rd July 2025 is ₹90.06. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Bafna Pharmaceuticals Ltd (BAFNAPH) share?
The past returns of Bafna Pharmaceuticals Ltd (BAFNAPH) share are- Past 1 week: 18.20%
- Past 1 month: 24.08%
- Past 3 months: 21.62%
- Past 6 months: 9.86%
- Past 1 year: 3.09%
- Past 3 years: -21.69%
- Past 5 years: 302.05%
What are the peers or stocks similar to Bafna Pharmaceuticals Ltd (BAFNAPH)?
The peers or stocks similar to Bafna Pharmaceuticals Ltd (BAFNAPH) include:What is the market cap of Bafna Pharmaceuticals Ltd (BAFNAPH) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bafna Pharmaceuticals Ltd (BAFNAPH) is ₹213.05 Cr as of 3rd July 2025.What is the 52 week high and low of Bafna Pharmaceuticals Ltd (BAFNAPH) share?
The 52-week high of Bafna Pharmaceuticals Ltd (BAFNAPH) is ₹96 and the 52-week low is ₹69.What is the PE and PB ratio of Bafna Pharmaceuticals Ltd (BAFNAPH) stock?
The P/E (price-to-earnings) ratio of Bafna Pharmaceuticals Ltd (BAFNAPH) is 51.34. The P/B (price-to-book) ratio is 2.64.Which sector does Bafna Pharmaceuticals Ltd (BAFNAPH) belong to?
Bafna Pharmaceuticals Ltd (BAFNAPH) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Bafna Pharmaceuticals Ltd (BAFNAPH) shares?
You can directly buy Bafna Pharmaceuticals Ltd (BAFNAPH) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Bafna Pharmaceuticals Ltd
BAFNAPH Share Price
90.060.00% (+0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
BAFNAPH Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is underpriced but is in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
BAFNAPH Performance & Key Metrics
BAFNAPH Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 51.34 | 2.64 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.76 | 6.53 | 0.82% |
BAFNAPH Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BAFNAPH Company Profile
Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines.
SUNPHARMA
PE Ratio
36.88
36.88
1Y Return
9.50%
9.50%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.11
23.11
1Y Return
1.68%
1.68%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
59.05
59.05
1Y Return
17.50%
17.50%
Buy Reco %
70.83
70.83
DRREDDY
PE Ratio
19.00
19.00
1Y Return
0.48%
0.48%
Buy Reco %
55.17
55.17
ZYDUSLIFE
PE Ratio
22.22
22.22
1Y Return
8.75%
8.75%
Buy Reco %
44.44
44.44
BAFNAPH Forecast
BAFNAPH Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BAFNAPH
BAFNAPH
Income
Balance Sheet
Cash Flow
Annual Normal View
BAFNAPH Income Statement
BAFNAPH Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 66.10 | 78.43 | 44.02 | 42.73 | 71.97 | 86.84 | 118.62 | 155.99 | 148.60 | 148.61 | ||||||||||
Raw Materials | 55.01 | 34.19 | 27.00 | 23.22 | 33.58 | 41.70 | 65.98 | 91.58 | 136.83 | 136.83 | ||||||||||
| Power & Fuel Cost | 2.01 | 2.12 | 2.50 | 2.69 | 2.95 | 3.93 | 5.31 | 6.73 | ||||||||||||
| Employee Cost | 6.62 | 7.47 | 9.01 | 10.25 | 11.98 | 14.65 | 15.87 | 19.03 | ||||||||||||
| Selling & Administrative Expenses | 3.15 | 4.07 | 3.13 | 3.18 | 2.67 | 6.92 | 5.39 | 13.98 | ||||||||||||
| Operating & Other expenses | 3.39 | 34.40 | 15.06 | 25.22 | 9.74 | 8.14 | 7.09 | 10.03 | ||||||||||||
EBITDA | -4.08 | -3.82 | -12.68 | -21.83 | 11.05 | 11.50 | 18.98 | 14.64 | 11.77 | 11.78 | ||||||||||
| Depreciation/Amortization | 3.89 | 3.65 | 3.42 | 3.27 | 4.48 | 5.49 | 5.33 | 5.00 | 4.89 | 4.90 | ||||||||||
| PBIT | -7.97 | -7.47 | -16.10 | -25.10 | 6.57 | 6.01 | 13.65 | 9.64 | 6.88 | 6.88 | ||||||||||
| Interest & Other Items | 11.34 | 6.81 | 2.13 | 0.10 | 0.74 | 0.79 | 2.04 | 2.29 | 2.73 | 2.73 | ||||||||||
| PBT | -19.31 | -14.28 | -18.23 | -25.20 | 5.83 | 5.22 | 11.61 | 7.35 | 4.15 | 4.15 | ||||||||||
| Taxes & Other Items | -0.84 | 2.18 | 1.50 | 0.00 | 0.00 | 0.00 | 0.28 | 0.00 | 0.00 | — | ||||||||||
| Net Income | -18.47 | -16.46 | -19.73 | -25.20 | 5.83 | 5.22 | 11.33 | 7.35 | 4.15 | 4.15 | ||||||||||
| EPS | -9.90 | -7.78 | -8.34 | -19.37 | 4.48 | 2.21 | 4.79 | 3.11 | 1.76 | 1.75 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
BAFNAPH Company Updates
BAFNAPH Stock Peers
BAFNAPH Past Performance & Peer Comparison
BAFNAPH Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bafna Pharmaceuticals Ltd | 51.34 | 2.64 | — |
| Sun Pharmaceutical Industries Ltd | 36.88 | 6.01 | 0.95% |
| Cipla Ltd | 23.11 | 3.89 | 1.06% |
| Torrent Pharmaceuticals Ltd | 59.05 | 16.46 | 0.96% |
BAFNAPH Stock Price Comparison
Compare BAFNAPH with any stock or ETFCompare BAFNAPH with any stock or ETF
BAFNAPH
BAFNAPH Holdings
BAFNAPH Shareholdings
BAFNAPH Promoter Holdings Trend
BAFNAPH Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 13.30%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BAFNAPH Institutional Holdings Trend
BAFNAPH Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has increased by 8.53%
BAFNAPH Shareholding Pattern
BAFNAPH Shareholding Pattern
BAFNAPH Shareholding History
BAFNAPH Shareholding History
Foreign Institutions
smallcases containing BAFNAPH stock
smallcases containing BAFNAPH stock
Looks like this stock is not in any smallcase yet.
BAFNAPH Events
BAFNAPH Events
BAFNAPH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BAFNAPH has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BAFNAPH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BAFNAPH has not given any dividends in last 5 years
BAFNAPH Upcoming Dividends
BAFNAPH Upcoming Dividends
No upcoming dividends are available
BAFNAPH Past Dividends
BAFNAPH Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2013
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 19, 2013
BAFNAPH Stock News & Opinions
BAFNAPH Stock News & Opinions
Articles & Videos
Earnings
Bafna Pharmaceuticals standalone net profit declines 10.27% in the March 2025 quarter
Net profit of Bafna Pharmaceuticals declined 10.27% to Rs 1.31 crore in the quarter ended March 2025 as against Rs 1.46 crore during the previous quarter ended March 2024. Sales declined 5.65% to Rs 39.06 crore in the quarter ended March 2025 as against Rs 41.40 crore during the previous quarter ended March 2024. For the full year,net profit declined 43.54% to Rs 4.15 crore in the year ended March 2025 as against Rs 7.35 crore during the previous year ended March 2024. Sales declined 4.34% to Rs 145.86 crore in the year ended March 2025 as against Rs 152.47 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales39.0641.40 -6 145.86152.47 -4 OPM %7.966.98 -7.667.29 - PBDT3.322.73 22 11.1912.35 -9 PBT3.101.46 112 6.307.35 -14 NP1.311.46 -10 4.157.35 -44 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Bafna Pharmaceuticals to table results
Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Bafna Pharmaceuticals reports standalone net profit of Rs 0.95 crore in the December 2024 quarter
Net profit of Bafna Pharmaceuticals reported to Rs 0.95 crore in the quarter ended December 2024 as against net loss of Rs 2.94 crore during the previous quarter ended December 2023. Sales rose 16.70% to Rs 33.19 crore in the quarter ended December 2024 as against Rs 28.44 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales33.1928.44 17 OPM %9.25-7.28 - PBDT2.62-1.67 LP PBT0.96-2.94 LP NP0.95-2.94 LP Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Bafna Pharmaceuticals announces board meeting date
Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Bafna Pharmaceuticals standalone net profit rises 5.65% in the September 2024 quarter
Net profit of Bafna Pharmaceuticals rose 5.65% to Rs 2.62 crore in the quarter ended September 2024 as against Rs 2.48 crore during the previous quarter ended September 2023. Sales declined 0.88% to Rs 40.32 crore in the quarter ended September 2024 as against Rs 40.68 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales40.3240.68 -1 OPM %9.429.83 - PBDT4.203.72 13 PBT2.622.48 6 NP2.622.48 6 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Bafna Pharmaceuticals to discuss results
Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Bafna Pharmaceuticals schedules AGM
Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Bafna Pharmaceuticals to convene AGM
Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Bafna Pharmaceuticals reports standalone net loss of Rs 0.72 crore in the June 2024 quarter
Net loss of Bafna Pharmaceuticals reported to Rs 0.72 crore in the quarter ended June 2024 as against net profit of Rs 6.35 crore during the previous quarter ended June 2023. Sales declined 20.64% to Rs 33.29 crore in the quarter ended June 2024 as against Rs 41.95 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales33.2941.95 -21 OPM %3.6314.99 - PBDT1.077.56 -86 PBT-0.376.35 PL NP-0.726.35 PL Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Bafna Pharmaceuticals to declare Quarterly Result
Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 28.31%, vs industry avg of 10.2%
Over the last 5 years, market share increased from 0.02% to 0.04%